Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
Nicola De StefanoFrederik BarkhofXavier MontalbanAnat AchironTobias DerfussAndrew ChanSuzanne HodgkinsonAlexandre PratLetizia LeocaniKlaus SchmiererFinn SellebjergPatrick VermerschHeinz WiendlBirgit KellerSanjeev Roynull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
Using frequent MRI assessments of the brain over the first 6 months of the MAGNIFY-MS study (NCT03364036), we aimed to determine the onset of action of cladribine tablets 3.5 mg/kg in adult patients with highly active relapsing MS. This study provides Class IV evidence that, in such patients, treatment with cladribine tablets is associated with an early onset of action with reductions in active MRI lesion counts from month 2 (day 60) onward, with an increasing reduction in such lesions over time.
Keyphrases
- multiple sclerosis
- early onset
- white matter
- magnetic resonance imaging
- mass spectrometry
- contrast enhanced
- ms ms
- end stage renal disease
- late onset
- newly diagnosed
- ejection fraction
- diffusion weighted imaging
- magnetic resonance
- disease activity
- prognostic factors
- systemic lupus erythematosus
- blood brain barrier
- patient reported